Life Scientist > Biotechnology

Drug boosts growth in children with dwarfism

01 July, 2019

Tested in a global trial, the drug regulates bone development and boosts growth rates in children with achondroplasia — the most common type of dwarfism.

New drug compound could tackle hereditary kidney disease

01 July, 2019

Mironid has developed a compound to treat autosomal dominant polycystic kidney disease — a hereditary, progressive disease that affects around 12 million people worldwide.

Hypertension drug holds promise for Alzheimer's disease

26 June, 2019

The blood pressure drug nilvadipine increases blood flow to the brain's memory and learning centre among people with Alzheimer's disease without affecting other parts of the brain.

Chemo-free leukaemia treatment approved by FDA

25 June, 2019

A trial into the treatment of chronic lymphocytic leukaemia has been so successful that the US FDA approved the treatment for patients with the disease prior to the trial data being presented.

Vic pharma manufacturer expands operations

21 June, 2019

Australian Pharmaceutical Manufacturers has opened expanded operations in the suburb of Keysborough, allowing the company to increase exports and create 44 new local jobs.

'Homing beacon' attracts chemo drugs to tumours

20 June, 2019

Scientists have added a 'homing beacon' to tumours, in the form of an injectable hydrogel, that attracts chemotherapy medicines towards cancer cells while sparing their normal counterparts.

New drug candidate for active rheumatoid arthritis

17 June, 2019

In a large-scale, international study, 12.5 to 20% of patients who were given the drug on a daily basis experienced so-called sustained remission — a state that is almost like being cured.

Universal flu vaccine passes development milestones

14 June, 2019

Vaccitech has administered its pandemic universal influenza A vaccine MVA-NP+M1 (VTP-100) to the first participants in a Flu 010 study.

Cannabis for cancer treatment on the agenda

07 June, 2019

MGC Pharmaceuticals has been granted a cannabis research licence in tandem with RMIT University, while Medlab Clinical has executed a heads of agreement for the further global distribution of its CBD/THC blend.

Synthetic molecules deliver drugs directly to neuroblastoma

06 June, 2019

Researchers synthesised a family of molecules that are able to specifically bind a protein found in the cell membrane of more than 90% of neuroblastoma cells.

Stem cell therapy can reverse osteoarthritis

05 June, 2019

Pure stem cells provide a more effective treatment for osteoarthritis than traditional therapies, such as pain relief drugs, anti-inflammatories, prescribed exercise and knee surgery.

Cell culture platform recreates tumours in 3D

29 May, 2019

Scientists can use a 3D tumour structure to test several drugs or their combinations at different stages of the tumour's development.

Scientists combine influenza and pneumococcal vaccines

23 May, 2019

Scientists have developed a single vaccination approach to simultaneously combat influenza and pneumococcal infections, while enhancing protection against both.

Biological tissue could be 3D printed

21 May, 2019

Researchers have been working to develop and optimise suitable bioinks for additive manufacturing, in the hope that we will soon be using 3D-printed biologically functional tissue to replace irreparably damaged tissue in the body.

Synthetic polymyxin antibiotics could take on superbugs

16 May, 2019

Monash University has granted an exclusive licence of its portfolio of proprietary synthetic polymyxin antibiotics to Qpex Biopharma.

  • All content Copyright © 2021 Westwick-Farrow Pty Ltd